*https://doi.org/10.48047/AFJBS.6.16.2024.4279-4286*

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

# Physiological Perspectives on Diabetes Complications: Unveiling the Underlying Mechanisms

**Sardar Ahmad, Madiha Noor, Hina Sadaf, Sadia Islam, Nusrat Tariq, Yusra Hameed, Farah Naz Tahir**

1. Assistant Professor, MBBS, DCH, MPH, MPhil Physiology, Gajju Khan Medical College, Swabi, sardarbkmc@gmail.com
2. MPhil Physiology, madihanoman69@gmail.com
3. Assistant Professor of Physiology, Azra Naheed Medical College, Lahore, heenaghaffar@gmail.com
4. MPhil Physiology, Associate Professor, Rashid Latif Medical College, sadia.murtaza98@yahoo.com
5. MBBS, MPhil, PhD (Physiology), Professor, M. Islam Medical & Dental College, Gujranwala, drnusrattariq@gmail.com
6. MBBS, Postgraduate Trainee, Al Nafees Medical College and Hospital, Islamabad, yusrahameed501@gmail.com
7. MBBS, MPhil, PhD, Associate Professor, Biochemistry Department, Central Park Medical College, Lahore, tahirnazfarah@gmail.com

Volume 6, Issue 16, Dec 2024

Received: 13 Aug 2024

Accepted: 11 Nov 2024

Published: 27 Dec 2024

*doi:10.48047/AFJBS.6.16.2024.4279-4286*

**Abstract**

**Background:**

Diabetes mellitus (DM) is a global health epidemic that leads to severe complications such as diabetic nephropathy, retinopathy, neuropathy, and cardiovascular diseases. These complications significantly contribute to morbidity and mortality in diabetic patients. Despite extensive research, the physiological mechanisms underlying the development of these complications remain incompletely understood. The relationship between hyperglycemia, insulin resistance, and vascular dysfunction is critical, but the exact pathways remain an area of active investigation.

**Objective:**

This study aims to explore the physiological mechanisms contributing to the development of diabetic complications, with a focus on the molecular and cellular mechanisms involved in endothelial dysfunction, inflammation, oxidative stress, and fibrosis. The goal is to better understand the pathophysiology of these complications to develop more effective therapeutic strategies.

**Methods:**

A cohort of 1,000 diabetic patients (Type 1 and Type 2) was assessed for the presence of diabetic complications. Serum and plasma biomarkers associated with inflammation, oxidative stress, and fibrosis were measured, and their relationship with clinical outcomes was analyzed. Additionally, animal models of diabetes were employed to study the underlying molecular pathways involved in endothelial dysfunction and tissue fibrosis. Gene expression analysis and protein assays were performed to assess molecular changes in diabetic tissues.

**Results:**

The results demonstrated significant increases in biomarkers of inflammation (e.g., C-reactive protein, TNF-α) and oxidative stress (e.g., malondialdehyde, superoxide dismutase) in patients with advanced diabetic complications. In animal models, endothelial dysfunction was shown to correlate with elevated levels of vascular endothelial growth factor (VEGF) and fibrosis markers, including collagen type I and fibronectin. Gene expression analysis revealed significant alterations in key signaling pathways, such as the PI3K/Akt pathway and TGF-β signaling, contributing to vascular remodeling and fibrosis. These findings provide insight into the molecular mechanisms that drive the development of complications in diabetes.

**Conclusion:**

The study confirms that chronic hyperglycemia and insulin resistance lead to endothelial dysfunction, increased oxidative stress, and activation of fibrotic pathways, which collectively contribute to the progression of diabetic complications. Targeting these pathways may offer new therapeutic strategies to prevent or mitigate diabetic complications. Future research should focus on the development of targeted interventions aimed at these molecular pathways to reduce the burden of diabetes-related complications.

**Keywords:**

Diabetes, Complications, Endothelial dysfunction, Oxidative stress, Inflammation, Fibrosis, Vascular remodeling, Molecular pathways.

## Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels due to either insulin deficiency (Type 1 diabetes) or insulin resistance (Type 2 diabetes). The global prevalence of diabetes has reached alarming levels, and the disease is associated with

a wide range of complications that affect various organ systems. Diabetic nephropathy, retinopathy, neuropathy, and cardiovascular diseases are among the most common and debilitating complications of diabetes, contributing to the high burden of morbidity and mortality. Understanding the underlying physiological mechanisms of these complications is crucial for developing targeted therapies to prevent or slow their progression[1-5].

The vascular system plays a central role in the development of many diabetes-related complications. Hyperglycemia, insulin resistance, and dyslipidemia lead to endothelial dysfunction, a key early event in the pathogenesis of diabetic complications. This dysfunction is characterized by reduced nitric oxide availability, increased oxidative stress, and enhanced inflammation, all of which contribute to vascular remodeling, fibrosis, and tissue injury. Additionally, hyperglycemia activates several signaling pathways, including the polyol pathway, advanced glycation end product (AGE) formation, and the protein kinase C (PKC) pathway, which further exacerbate vascular damage[6-8].

Moreover, oxidative stress, a hallmark of chronic hyperglycemia, plays a pivotal role in the development of diabetic complications. Elevated glucose levels increase the production of reactive oxygen species (ROS), which in turn leads to endothelial cell damage, reduced nitric oxide bioavailability, and vascular dysfunction. The accumulation of ROS also activates pro-inflammatory pathways, further aggravating endothelial injury. Additionally, persistent oxidative stress can activate the renin-angiotensin system (RAS), which contributes to the development of diabetic nephropathy and hypertension[9-11].

The molecular mechanisms driving fibrosis in diabetic tissues are equally important in the progression of diabetic complications. Fibrosis is characterized by excessive extracellular matrix deposition, leading to tissue stiffening and dysfunction. In diabetic patients, the activation of transforming growth factor-beta (TGF-β) signaling and other fibrotic pathways has been implicated in the development of fibrosis in the kidneys, heart, and other organs. Fibrosis is thought to be driven by chronic inflammation, oxidative stress, and the dysregulation of extracellular matrix remodeling.

Despite significant advances in our understanding of the molecular mechanisms underlying diabetes complications, many questions remain unanswered. For example, the exact role of specific signaling pathways in endothelial dysfunction and fibrosis is still not fully understood. Furthermore, the interplay between hyperglycemia, insulin resistance, and inflammation is

complex and not fully elucidated. Thus, continued research is needed to identify novel therapeutic targets and develop strategies to mitigate or prevent the onset of diabetic complications.

This study aims to provide a comprehensive understanding of the physiological mechanisms that contribute to diabetic complications, with a focus on endothelial dysfunction, oxidative stress, inflammation, and fibrosis. By exploring the molecular pathways involved in these processes, this research seeks to identify potential targets for therapeutic intervention, ultimately improving the quality of life for individuals living with diabetes.

**Methods**

This prospective cohort study included 1,000 patients diagnosed with diabetes (Type 1 and Type 2) at a Gajju Khan Medical College, Swabi tertiary healthcare center. All participants provided informed consent, and the study protocol was approved by the institutional review board. Clinical data were collected, including patient demographics, medical history, duration of diabetes, blood glucose levels, and presence of diabetic complications such as nephropathy, retinopathy, neuropathy, and cardiovascular disease.

Blood samples were collected from all participants for the measurement of biomarkers associated with inflammation (C-reactive protein, TNF-α), oxidative stress (malondialdehyde, superoxide dismutase), and fibrosis (collagen type I, fibronectin). Urine samples were collected to assess albuminuria, a marker of diabetic nephropathy. The glomerular filtration rate (GFR) was estimated using the CKD-EPI equation. Retinal images were obtained to assess the presence of diabetic retinopathy, and nerve conduction studies were performed to evaluate diabetic neuropathy.

In parallel, animal models of Type 1 and Type 2 diabetes were utilized to investigate the molecular pathways involved in endothelial dysfunction and fibrosis. Mice were treated with streptozotocin to induce diabetes, and their vascular function was assessed using wire myography and endothelial cell assays. Tissues were collected for gene expression analysis and protein assays to evaluate the activation of signaling pathways such as the PI3K/Akt pathway and TGF-β signaling.

**Results**

## Table 1: Biomarker Levels in Diabetic Patients with and without Complications

| Biomarker | Diabetes Without Complications (Mean ± SD) | Diabetes With Complications (Mean ± SD) | p-value |
|---|---|---|---|
| C-Reactive Protein (CRP) (mg/L) | 3.2 ± 1.1 | 6.8 ± 1.5 | <0.001 |
| TNF-α (pg/mL) | 12.5 ± 2.3 | 25.4 ± 3.8 | <0.001 |
| Malondialdehyde (MDA) (µmol/L) | 2.1 ± 0.6 | 4.5 ± 1.1 | <0.001 |
| Superoxide Dismutase (SOD) (U/mL) | 110.2 ± 15.6 | 72.3 ± 12.8 | <0.001 |
| Collagen Type I (ng/mL) | 220.5 ± 30.2 | 380.7 ± 45.6 | <0.001 |
| Fibronectin (µg/mL) | 1.8 ± 0.3 | 3.2 ± 0.5 | <0.001 |

## Table 2: Gene Expression Analysis in Animal Models of Diabetic Complications

| Gene/Protein | Normal Mice (Fold Change) | Diabetic Mice (Fold Change) | p-value |
|---|---|---|---|
| Vascular Endothelial Growth Factor (VEGF) | 1.0 (Baseline) | 3.8 ± 0.6 | <0.001 |
| Transforming Growth Factor-Beta (TGF-β) | 1.0 (Baseline) | 4.5 ± 0.9 | <0.001 |
| PI3K/Akt Pathway Activation | 1.0 (Baseline) | 2.9 ± 0.5 | <0.001 |
| Collagen Type I Expression | 1.0 (Baseline) | 5.1 ± 1.2 | <0.001 |
| ROS Levels | 1.0 (Baseline) | 4.3 ± 0.7 | <0.001 |
| Nitric Oxide (NO) Production | 1.0 (Baseline) | 0.4 ± 0.1 | <0.001 |

The study found a significant increase in biomarkers of inflammation and oxidative stress in patients with advanced diabetic complications. C-reactive protein (CRP) levels were elevated in 65% of patients with diabetic nephropathy, 58% of patients with retinopathy, and 72% of patients with neuropathy. Similarly, markers of oxidative stress, such as malondialdehyde (MDA) and

superoxide dismutase (SOD), were significantly higher in patients with complications compared to those without.

In animal models, endothelial dysfunction was demonstrated by a significant reduction in nitric oxide (NO) production and an increase in ROS levels in diabetic mice. The gene expression of vascular endothelial growth factor (VEGF) and fibrotic markers such as collagen type I and fibronectin was significantly upregulated in the kidneys and heart tissues of diabetic animals.

Gene expression analysis revealed that key signaling pathways, including PI3K/Akt and TGF-β, were activated in the endothelial cells of diabetic mice, leading to vascular remodeling and fibrosis. Additionally, histological analysis of diabetic tissues showed increased extracellular matrix deposition and tissue stiffening.

**Discussion**

This study provides significant insights into the molecular and physiological mechanisms that drive the development of diabetic complications[12]. The results suggest that inflammation and oxidative stress play central roles in the onset and progression of complications, particularly in the vasculature. Increased ROS production and reduced nitric oxide availability contribute to endothelial dysfunction, which is a key early event in the development of diabetic nephropathy, retinopathy, and cardiovascular diseases[13-15]. The upregulation of VEGF and fibrotic markers further highlights the importance of vascular remodeling and fibrosis in diabetic complications.

The activation of the PI3K/Akt and TGF-β signaling pathways was found to be critical in the development of endothelial dysfunction and fibrosis. These pathways are involved in cellular survival, proliferation, and extracellular matrix deposition, suggesting that therapeutic strategies targeting these pathways may offer promise in preventing or mitigating diabetic complications.

While the findings of this study contribute to our understanding of the pathophysiology of diabetes complications, several challenges remain[16-18]. The complexity of the molecular interactions involved in diabetic complications requires further investigation to identify additional therapeutic targets. Moreover, the translation of these findings into clinical practice will require the development of effective diagnostic tools and therapies that can be used in the management of diabetic patients[19-20].

**Conclusion**

In conclusion, this study underscores the importance of inflammation, oxidative stress, and fibrosis in the development of diabetic complications. Understanding the molecular pathways involved in endothelial dysfunction and tissue remodeling opens the door for targeted therapeutic interventions aimed at preventing or treating these complications. Further research is needed to refine these therapeutic strategies and enhance their clinical application, ultimately improving outcomes for diabetic patients.

**References**

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-1625.
2. Sowers JR, Whaley-Connell A, Weir MR. Obesity, insulin resistance, and diabetes: implications for endothelial dysfunction. J Am Coll Cardiol. 2009;53(5):466-473.
3. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058-1070.
4. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress, and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148(2):209-214.
5. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97(2A):3A-11A.
6. Wu H, Ballantyne CM. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and cardiovascular disease. Circulation. 2017;135(1):e85-e97.
7. Niskanen L, Laakso M. The metabolic syndrome and the risk of cardiovascular disease. Curr Diab Rep. 2004;4(6):353-358.
8. Khan A, Mohanty P, Ehsan A, et al. Role of oxidative stress in the pathogenesis of diabetic complications. Int J Diabetes Mellitus. 2013;1(4):271-276.
9. Draznin B. Molecular mechanisms of insulin resistance. J Clin Invest. 2006;116(7):1747-1754.
10. Chiarelli F, Marcovecchio ML. Insulin resistance and endothelial dysfunction in children and adolescents. Diabetes Care. 2008;31(2):352-360.
11. McVicar CM, Jackson S, Adams D, et al. Enhanced oxidative stress and DNA damage in type 2 diabetic patients with microvascular complications. Diabet Med. 2010;27(8):946-953.

12. Wendt T, Tanji N, Qu W, et al. Advanced glycation end products and the pathogenesis of diabetic complications. Diabetes. 2003;52(12):409-416.
13. Cai L, Wang X, Wang Y, et al. Increased reactive oxygen species in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol. 2003;14(8):1882-1891.
14. Koya D, Hayashi K, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1997;46(7):1191-1197.
15. Gao Y, Zhang L, Shen B, et al. Effects of angiotensin II on the proliferation and migration of mesangial cells in diabetic nephropathy. Am J Physiol Renal Physiol. 2009;296(6):F1272-F1280.
16. Xie P, Zhang Y, Zhang L, et al. Transforming growth factor-beta and its role in fibrosis in diabetes. Curr Diabetes Rev. 2015;11(5):396-403.
17. Li J, Zhang L, Xie P, et al. Endothelial dysfunction in diabetes and therapeutic approaches. Curr Pharm Des. 2015;21(25):3747-3758.
18. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251(2):87-101.
19. Lupu C, Popescu F, Mirea A. Advances in the molecular mechanisms of diabetic complications: a review. Acta Endocrinol (Buc). 2020;16(4):535-541.
20. Sahay M, Ghosh A, Ghosal S. Molecular mechanisms involved in diabetic complications and therapeutic intervention. Free Radic Biol Med. 2019;130:1-10.